V-Wave™ Ventura Interatrial Shunt
HFrEF: A Critical Unmet Need
Approximately 50% of heart failure cases worldwide have reduced LVEF accompanied by progressive left ventricular dilatation and adverse cardiac remodeling.1,2 HFrEF is a major public health concern with substantial morbidity and mortality.1
V-Wave Ventura Interatrial Shunt
The V-Wave Ventura Interatrial Shunt is a unique, hourglass-shaped shunt designed to reduce increases in left atrial pressure by offloading volume from the left atrium to the right atrium.3
About Us
V-Wave Ltd., was established in Israel in 2009 with a focus on developing a percutaneous implantable shunt for patients with chronic heart failure. Johnson & Johnson acquired V-Wave on October 9, 2024, and we are now proudly part of Johnson& Johnson MedTech.
References
Murphy SP, Ibrahim NE, Januzzi JL, Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. Aug 2020;324(5):488-504. doi:10.1001/jama.2020.10262
Golla M, Shams P. Heart failure with preserved ejection fraction (HFpEF). StatLPearls (Internet). StatPear Publishing; 2025.
Patent numbers: 10251740, 10076403, 11850138 https://ppubs.uspto.gov/pubwebapp/static/pages/ ppubsbasic.html
MP-0005691 rev 2.0